Literature DB >> 23267867

Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase.

Frederike G I van Vilsteren1, K Nadine Phoa, Lorenza Alvarez Herrero, Roos E Pouw, Carine M T Sondermeijer, Ineke van Lijnschoten, Kees A Seldenrijk, Mike Visser, Sybren L Meijer, Mark I van Berge Henegouwen, Bas L A M Weusten, Erik J Schoon, Jacques J G H M Bergman.   

Abstract

BACKGROUND & AIMS: The current procedure for circumferential balloon-based radiofrequency ablation (c-RFA) for the removal of dysplastic Barrett's esophagus (BE) is labor intensive, comprising 2 ablation passes with a cleaning step to remove debris from the ablation zone and electrode. We compared the safety and efficacy of 3 different c-RFA ablation regimens.
METHODS: We performed a prospective trial of consecutive patients with flat-type BE with high-grade dysplasia. Fifty-seven patients (45 men; age, 64 ± 15 y; 28 with prior endoscopic resection) were assigned randomly to groups that underwent c-RFA with a double application of RFA (12 J/cm(2)). The standard group received c-RFA, with device removal and cleaning, followed by c-RFA; the simple-with-cleaning group underwent c-RFA, with device cleaning without removal, followed by c-RFA; and the simple-no-cleaning group received 2 applications of c-RFA, and the device was not removed or cleaned. The primary outcome was surface regression of BE 3 months later, graded by 2 blinded expert endoscopists. Calculated sample size was 57 patients, based on a noninferiority design.
RESULTS: Median BE surface regression at 3 months was 83% in the standard group, 78% in the simple-with-cleaning group, and 88% in the simple-no-cleaning group (P = .14). RF ablation time was 20 minutes (interquartile range [IQR], 18-25 min) for the standard group, 13 minutes (IQR, 11-15 min) for the simple-with-cleaning group, and 5 minutes (IQR, 5-9 min) for the simple-no-cleaning group (P < .01). The median number of introductions (RFA devices/endoscope) for the standard group was 7, vs 4 for the simple groups (P < .01).
CONCLUSIONS: This randomized, prospective study suggests that c-RFA is easier and faster, but equally safe and effective, when the cleaning phase between ablations is omitted or simplified. Trialregister.nl, NTR 2495.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23267867     DOI: 10.1016/j.cgh.2012.12.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  10 in total

Review 1.  Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus.

Authors:  Spyridon Michopoulos
Journal:  Ann Transl Med       Date:  2018-07

2.  Quality indicators for Barrett's endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett's neoplasia.

Authors:  Durayd Alzoubaidi; Krish Ragunath; Sachin Wani; Ian D Penman; Nigel John Trudgill; Marnix Jansen; Matthew Banks; Pradeep Bhandari; Allan John Morris; Robert Willert; Phil Boger; Howard L Smart; Narayanasamy Ravi; Jason Dunn; Charles Gordon; Jayan Mannath; Inder Mainie; Massi di Pietro; Andrew M Veitch; Sally Thorpe; Cormac Magee; Martin Everson; Sarmed Sami; Paul Bassett; David Graham; Stephen Attwood; Oliver Pech; Prateek Sharma; Laurence B Lovat; Rehan Haidry
Journal:  Frontline Gastroenterol       Date:  2019-08-14

Review 3.  Update on ablation for Barrett's esophagus.

Authors:  Gary W Falk
Journal:  Curr Gastroenterol Rep       Date:  2014-01

4.  Managing Barrett's esophagus with radiofrequency ablation.

Authors:  Junichi Akiyama; Andrew Roorda; George Triadafilopoulos
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-03-26

Review 5.  Ablative therapy for esophageal dysplasia and early malignancy: focus on RFA.

Authors:  Rebecca Tuttle; Steven J Nurkin; Steven N Hochwald
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

6.  Current Controversies in Radiofrequency Ablation Therapy for Barrett's Esophagus.

Authors:  Kamar Belghazi; Ilaria Cipollone; Jacques J G H M Bergman; Roos E Pouw
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03

7.  Standard versus simplified radiofrequency ablation protocol for Barrett's esophagus: comparative analysis of the whole treatment pathway.

Authors:  Wei Keith Tan; Krish Ragunath; Jonathan R White; Jose Santiago; Jacobo Ortiz Fernandez-Sordo; Mirela Pana; Bincy Alias; Andreas V Hadjinicolaou; Vijay Sujendran; Massimiliano di Pietro
Journal:  Endosc Int Open       Date:  2020-01-22

8.  UK guidelines on oesophageal dilatation in clinical practice.

Authors:  Sarmed S Sami; Hasan N Haboubi; Yeng Ang; Philip Boger; Pradeep Bhandari; John de Caestecker; Helen Griffiths; Rehan Haidry; Hans-Ulrich Laasch; Praful Patel; Stuart Paterson; Krish Ragunath; Peter Watson; Peter D Siersema; Stephen E Attwood
Journal:  Gut       Date:  2018-02-24       Impact factor: 23.059

9.  A single-step sizing and radiofrequency ablation catheter for circumferential ablation of Barrett's esophagus: Results of a pilot study.

Authors:  K Belghazi; R E Pouw; Cmt Sondermeijer; S L Meijer; E J Schoon; A D Koch; Blam Weusten; Jjghm Bergman
Journal:  United European Gastroenterol J       Date:  2018-04-11       Impact factor: 4.623

10.  Radiofrequency ablation for Barrett's oesophagus related neoplasia with the 360 Express catheter: initial experience from the United Kingdom and Ireland-preliminary results.

Authors:  Cormac G Magee; David Graham; Charles Gordon; Jason Dunn; Ian Penman; Robert Willert; Howard Smart; Jacobo Ortiz-Fernandez-Sordo; Krish Ragunath; Martin Everson; Durayd Alzoubaidi; Matthew Banks; Danielle Morris; Sarmed Sami; Allan J Morris; Pradeep Bhandari; Ravi Narayanasamy; Massimiliano Di Pietro; Laurence B Lovat; Rehan Haidry
Journal:  Surg Endosc       Date:  2021-02-05       Impact factor: 4.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.